Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Combined SAD/MAD Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of AST 008 in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Randomized, Combined SAD/MAD Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of AST 008 in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cavrotolimod (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions
  • Sponsors Exicure

    • Most Recent Events

    • 03 Apr 2019 Results presented at the 110th Annual Meeting of the American Association for Cancer Research
    • 01 Apr 2019 According to an Exicure media release, data from this trial will be presented at the American Association for Cancer Research (AACR) annual meeting 2019.
    • 16 Nov 2018 Results presented at the 30th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top